BRAF D594G
|
NSCLC
|
BRAF D594G
|
NSCLC
|
trametinib Resistant: C3 – Early Trials
|
trametinib Resistant: C3 – Early Trials
|
BRAF D594G
|
NSCLC
|
BRAF D594G
|
NSCLC
|
trametinib + dabrafenib Resistant: C3 – Early Trials
|
trametinib + dabrafenib Resistant: C3 – Early Trials
|
BRAF D594G
|
Ampulla of Vater Carcinoma
|
BRAF D594G
|
Ampulla of Vater Carcinoma
|
encorafenib + binimetinib Sensitive: C3 – Early Trials
|
encorafenib + binimetinib Sensitive: C3 – Early Trials
|
BRAF D594G
|
Melanoma
|
BRAF D594G
|
Melanoma
|
BVD-523 Sensitive: C3 – Early Trials
|
BVD-523 Sensitive: C3 – Early Trials
|
BRAF D594G
|
CRC
|
BRAF D594G
|
CRC
|
cetuximab + encorafenib + BVD-523 Sensitive: C3 – Early Trials
|
cetuximab + encorafenib + BVD-523 Sensitive: C3 – Early Trials
|